Literature DB >> 33437682

Urgent need to improve programmatic management of patients with HIV failing first-line antiretroviral therapy.

H Sunpath1,2, T J Hatlen3, M-Y S Moosa2, R A Murphy4, M Siedner5, K Naidoo1,6.   

Abstract

INTRODUCTION: Delayed identification and response to virologic failure in case of first-line antiretroviral therapy (ART) in resource-limited settings is a threat to the health of HIV-infected patients. There is a need for the implementation of an effective, standardized response pathway in the public sector. DISCUSSION: We evaluated published cohorts describing virologic failure on first-line ART. We focused on gaps in the detection and management of treatment failure, and posited ways to close these gaps, keeping in mind scalability and standardization. Specific shortcomings repeatedly recorded included early loss to follow-up (>20%) after recognized first-line ART virologic failure; frequent delays in confirmatory viral load testing; and excessive time between the confirmation of first-line ART failure and initiation of second-line ART, which exceeded 1 year in some cases. Strategies emphasizing patient tracing, resistance testing, drug concentration monitoring, adherence interventions, and streamlined response pathways for those failing therapy are further discussed.
CONCLUSION: Comprehensive, evidence-based, clinical operational plans must be devised based on findings from existing research and further tested through implementation science research. Until this standard of evidence is available and implemented, high rates of losses from delays in appropriate switch to second-line ART will remain unacceptably common and a threat to the success of global HIV treatment programs.
© 2020 The Union.

Entities:  

Keywords:  90-90-90; implementation research; virologic failure

Year:  2020        PMID: 33437682      PMCID: PMC7790490          DOI: 10.5588/pha.20.0052

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  41 in total

1.  Targeting the third '90': introducing the viral load champion.

Authors:  H Sunpath; T J Hatlen; K K Naidu; P Msimango; R N Adams; M-Y S Moosa; V C Marconi; R A Murphy; R T Gandhi; S Pillay; M Siedner; K Naidoo
Journal:  Public Health Action       Date:  2018-12-21

2.  Effectiveness of interventions for unstable patients on antiretroviral therapy in South Africa: results of a cluster-randomised evaluation.

Authors:  Matthew P Fox; Sophie J S Pascoe; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt
Journal:  Trop Med Int Health       Date:  2018-10-24       Impact factor: 2.622

3.  Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.

Authors:  Victoria Johnston; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

4.  Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa.

Authors:  Elvin H Geng; Nneka Emenyonu; Mwebesa Bosco Bwana; David V Glidden; Jeffrey N Martin
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

5.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Authors:  Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

6.  Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland.

Authors:  Kiran Jobanputra; Lucy Anne Parker; Charles Azih; Velephi Okello; Gugu Maphalala; Bernard Kershberger; Mohammed Khogali; Johnny Lujan; Annick Antierens; Roger Teck; Tom Ellman; Rose Kosgei; Tony Reid
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

7.  Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.

Authors:  Victor Ssempijja; Gertrude Nakigozi; Larry Chang; Ron Gray; Maria Wawer; Anthony Ndyanabo; Jingo Kasule; David Serwadda; Barbara Castelnuovo; Anja Van't Hoog; Steven James Reynolds
Journal:  BMC Infect Dis       Date:  2017-08-22       Impact factor: 3.090

8.  Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues.

Authors:  Talent Bvochora; Srinath Satyanarayana; Kudakwashe C Takarinda; Hilda Bara; Prosper Chonzi; Brian Komtenza; Clemence Duri; Tsitsi Apollo
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

9.  Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.

Authors:  Mario Cruciani; Saverio G Parisi
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240

10.  What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?

Authors:  Diane Havlir; Shahin Lockman; Helen Ayles; Joseph Larmarange; Gabriel Chamie; Tendani Gaolathe; Collins Iwuji; Sarah Fidler; Moses Kamya; Sian Floyd; Janet Moore; Richard Hayes; Maya Petersen; Francois Dabis
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.